Methyl-CpG-binding domain protein 3 mRNA (MBD3 mRNA)

Methyl-CpG-binding domain protein 3 (MBD3) mRNA encodes a core structural component of the Nucleosome Remodeling and Deacetylase (NuRD) complex, which is essential for gene silencing and chromatin remodeling [1]. Unlike other MBD family members, human MBD3 does not bind specifically to methylated DNA but serves as a scaffold for the NuRD complex assembly [1, 4]. MBD3 is a critical regulator of embryonic stem cell pluripotency and has been identified as a primary barrier to the induction of pluripotency in somatic cells [2]. In the context of disease, MBD3 is frequently overexpressed in various malignancies, including hepatocellular carcinoma and breast cancer, where it promotes tumor progression and chemoresistance [3]. Targeting MBD3 mRNA via RNA interference (siRNA) or antisense oligonucleotides (ASOs) is an emerging strategy to downregulate MBD3 protein levels and disrupt the NuRD complex [2, 3]. This approach aims to sensitize cancer cells to existing therapies or enhance the efficiency of cellular reprogramming for regenerative medicine [2]. However, therapeutic challenges include ensuring delivery to target tissues and minimizing off-target effects on normal epigenetic processes [3, 4].

Other names

MBD3Methyl-CpG binding domain protein 3Methyl-CpG-binding protein MBD3

RNA interference and antisense-mediated degradation of mRNA to reduce MBD3 protein levels